In 2025, the Indian animal health market stood at...

When Regeneron Pharmaceuticals and Bayer AG signed a licensing...

Feeding pigeons may feel harmless — but for many...

There was a phase when the industry feared that digital would eventually replace the medical sales representative but it appears that digital engagements work best when facilitated by an affable and knowledgeable person, who can personalize the information, and the conversation, to the doctor. In pharma, there’s no substituting face-to-face dialogue it seems. And why should it? “Rather than digital replacing a person in pharma, the need of the hour is digitalizing the approach of person. The person and the technology are HERE TO STAY”, says Archis Joshi, Commercial Head at Dr. Reddy’s. The sales role is getting tougher. Medical information, at one point pharma’s greatest value, is today much more freely available than it used to be. In the Indian market which is dominated by generic medicines lacking differentiation, simply informing doctors about the product, isn’t a viable prospect any more when it comes to piquing their interest. “Why are brands that have been around for some time still unable to cross the marketing funnel and are still stuck at either the ‘awareness’ or the ‘interest’ stages, and unable to move towards the ‘purchase’ or ‘recommendation’ stages?” wonders Mehul Shukla, Director, Marketing Excellence at Cipla.

If a business fails, it was an idea that didn’t work. If treatment fails – it must be a botch up. A broken gadget may be beyond repair, but not a patient in a doctor’s hands. From such ungraded expectations stems the potential for things to take an ugly turn. An unwanted profession dealing with an unwanted condition, namely Ill health: If possible, we would wish away death and diseases, hospitals and doctors. A hospital is not a holiday resort, but it too costs money. And the scenario of an adverse outcome like death simply becomes unacceptable.

Executive Summary The geopolitical landscape of pharmaceutical manufacturing is shifting...

The July Brand Monitor by Pharmarack shows a healthy...

The Two-Tier Reality of Indian Pharma: Patient Safety, Pharmacovigilance,...

In a written reply in the Lok Sabha in...

With extensive experience across commercial excellence, analytics, insights, AI-driven...

Executive Summary The geopolitical landscape of pharmaceutical manufacturing is shifting...

The July Brand Monitor by Pharmarack shows a healthy...

The Two-Tier Reality of Indian Pharma: Patient Safety, Pharmacovigilance,...

In a written reply in the Lok Sabha in...

With extensive experience across commercial excellence, analytics, insights, AI-driven...

Executive Summary The geopolitical landscape of pharmaceutical manufacturing is shifting...

The July Brand Monitor by Pharmarack shows a healthy...

The Two-Tier Reality of Indian Pharma: Patient Safety, Pharmacovigilance,...

In a written reply in the Lok Sabha in...

With extensive experience across commercial excellence, analytics, insights, AI-driven...

Executive Summary The geopolitical landscape of pharmaceutical manufacturing is shifting...

The July Brand Monitor by Pharmarack shows a healthy...

The Two-Tier Reality of Indian Pharma: Patient Safety, Pharmacovigilance,...

In a written reply in the Lok Sabha in...

With extensive experience across commercial excellence, analytics, insights, AI-driven...